PPM1G Inhibits Epithelial–Mesenchymal Transition in Cholangiocarcinoma by Catalyzing TET1 Dephosphorylation for Destabilization to Impair Its Targeted Demethylation of the CLDN3 Promoter
2024

PPM1G Inhibits Epithelial–Mesenchymal Transition in Cholangiocarcinoma

Sample size: 36 publication 10 minutes Evidence: high

Author Information

Author(s): W. Liu, Y. Kuai, D. Wang, J. Chen, F. Xiong, G. Wu, Q. Wang, W. Huang, Y. Qi, B. Wang, Y. Chen

Primary Institution: Tongji Medical College Huazhong University of Science and Technology

Hypothesis

PPM1G may serve as a therapeutic target to impede cholangiocarcinoma progression by destabilizing TET1.

Conclusion

PPM1G can be targeted to inhibit the progression of cholangiocarcinoma by destabilizing TET1, which is crucial for promoting EMT through CLDN3 transcription.

Supporting Evidence

  • TET1 is highly expressed in cholangiocarcinoma and correlates with poor prognosis.
  • PPM1G destabilizes TET1, impairing its ability to promote CLDN3 transcription.
  • Phosphatase inhibitors can reduce TET1 levels and inhibit cholangiocarcinoma cell proliferation.

Takeaway

This study shows that a protein called PPM1G can help stop a type of cancer by making another protein, TET1, less stable, which in turn helps control a gene important for cancer growth.

Methodology

The study utilized immunohistochemical analysis, RNA sequencing, and various in vitro and in vivo experiments to assess the role of TET1 and PPM1G in cholangiocarcinoma.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1002/advs.202407323

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication